Nexium Direct: AstraZeneca’s Ambitious Test Of Direct-To-Consumer Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Nexium will ship directly to patients as the drug is about to become victim to generic competition, signaling AstraZeneca’s satisfaction with its Arimidex program.
You may also be interested in...
Sun’s Ranbaxy Buy Out Could Have Implications For Nexium Generics
Ranbaxy’s ability to launch generic versions of AstraZeneca’s blockbuster Nexium in the U.S. on May 27 was uncertain already. Sun’s proposed $4 billion acquisition of Ranbaxy could further distract the troubled Indian generics firm from achieving that goal.
Teva’s Generic Viagra Launch Will Be Offset By Generic Cialis
Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.